DIABETIC MACULAR EDEMA

This study tests a gene therapy called 4D-150 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. The goal is to see if a single injection of the gene therapy can reduce the need for frequent eye injections over two years. About 72 adults …

This study follows about 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see how …

This study looks at how well the eye medicine faricimab works in Black, Hispanic, Native American, and Asian Indian patients with diabetic macular edema, a diabetes-related eye disease that can cause vision loss. About 218 adults who have not been treated before will receive fari…

This study tests a new medicine (RO7497372) given as an eye injection for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. The trial has two parts: the first checks safety and how the drug moves through the body, and the second comp…

This study tests a flexible 'treat and extend' approach for faricimab injections against the standard fixed schedule in people with diabetic macular edema. About 446 adults with vision loss from this condition will receive either schedule to see if the flexible plan works just as…

This study tests whether tonabersat can reduce retinal swelling in people with diabetic macular edema who still have good vision. About 128 adults with type 1 or 2 diabetes will receive either tonabersat or a placebo. The main goal is to see if the drug decreases the thickness of…

This study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks. It includes about 1,100 adults with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME) who have already received anti-VEGF treatment. The main goal is t…

This early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes blurry vision in people with diabetes. The main goal is to check the drug's safety and how the body processes it. Ab…

This study tests a new medicine called RO7446603 for people with diabetic macular edema, a condition that causes vision loss due to swelling in the back of the eye. The trial has two parts: first, checking safety of the drug alone or with other eye injections; second, comparing a…

This study looks at adults with diabetic macular edema (swelling in the back of the eye) who didn't get enough help from standard anti-VEGF injections. They are given a dexamethasone implant that slowly releases steroid medicine into the eye. Researchers will track how many extra…

This study tests a more proactive treatment plan for diabetic macular edema, a condition that causes vision loss. Instead of waiting for severe swelling to return, participants receive two steroid implants within 12 weeks, then additional injections only as needed. The goal is to…

This study tests whether giving ONS-5010 (a bevacizumab eye injection) from a pre-filled syringe is as safe as using a standard vial. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will take part. The main goal…

This study is gathering long-term information from about 6,000 people receiving Roche eye medications for conditions like age-related macular degeneration and diabetic eye disease. The goal is to see how well these treatments work in everyday medical practice, not in a controlled…

This study watches about 110 adults with diabetic macular edema who are already receiving OZURDEX implants as part of their normal care in China. Researchers will track side effects and eye health for 24 months after the first dose, plus a 30-day follow-up. No extra treatments or…